Levade T, Gatt S, Maret A, Salvayre R
Laboratoire de Biochimie, C.H.U. Rangueil, Toulouse Cédex, France.
J Biol Chem. 1991 Jul 25;266(21):13519-29.
The metabolism of sphingomyelin (SPM) was investigated in Epstein-Barr virus-transformed lymphoid cell lines from normal individuals and from patients with Niemann-Pick disease Type A (deficient in the acid, lysosomal sphingomyelinase) and familial hypercholesterolemia (lacking the low density lipoprotein receptor). Cells were incubated with the following radioactive or fluorescent SPMs: [choline-methyl-14C] SPM, [oleoyl-3H]SPM, pyrene-propenoyl-SPM (P3:1-SPM), pyrene-butanoyl-SPM (P4-SPM), pyrene-dodecanoyl-SPM (P12-SPM), and pyrene-sulfonylamino-undecanoyl-SPM (PSA11-SPM). Several pathways of uptake and subsequent metabolism of SPM in the lymphoblastoid cells were identified. [choline-methyl-14C]SPM and the P12-analog, administered to the cells in the presence of lipoproteins, were taken up through the apoB/E receptor-dependent pathway of endocytosis and degraded solely by the lysosomal sphingomyelinase. Under similar conditions, the other sphingomyelins, i.e. [oleoyl-3H]SPM, P3:1-SPM, P4-SPM, and PSA11-SPM, were taken up by a low density lipoprotein receptor-independent pathway and degraded mostly by a nonlysosomal sphingomyelinase which also catalyzed their hydrolysis in Niemann-Pick cells. In the absence of serum, all sphingomyelins were taken up by an apoB/E receptor-independent pathway and hydrolyzed by a nonlysosomal sphingomyelinase. Indeed, in vitro assays demonstrated the presence, in lymphoblastoid cells, of the neutral magnesium-activated sphingomyelinase, which was also fully active in the Niemann-Pick cells. In conclusion, our observations are consistent with: (i) the existence in lymphoblastoid cells of several pathways for the uptake and subsequent utilization of SPM; (ii) a major role of lipoproteins for the metabolic routing of the SPM; and (iii) the effect of the structure of the fatty acyl residue of SPM on its possible association with lipoproteins and/or cell membranes.
研究了来自正常个体、A型尼曼-匹克病患者(酸性溶酶体鞘磷脂酶缺乏)和家族性高胆固醇血症患者(低密度脂蛋白受体缺乏)的爱泼斯坦-巴尔病毒转化淋巴母细胞系中鞘磷脂(SPM)的代谢。将细胞与以下放射性或荧光性鞘磷脂一起孵育:[胆碱-甲基-¹⁴C]鞘磷脂、[油酰基-³H]鞘磷脂、芘丙烯酰基鞘磷脂(P3:1-SPM)、芘丁酰基鞘磷脂(P4-SPM)、芘十二烷酰基鞘磷脂(P12-SPM)和芘磺酰氨基十一烷酰基鞘磷脂(PSA11-SPM)。确定了淋巴母细胞中鞘磷脂摄取及后续代谢的几种途径。在脂蛋白存在的情况下给予细胞的[胆碱-甲基-¹⁴C]鞘磷脂和P12类似物,通过载脂蛋白B/E受体依赖性内吞途径被摄取,并仅由溶酶体鞘磷脂酶降解。在类似条件下,其他鞘磷脂,即[油酰基-³H]鞘磷脂、P3:1-SPM、P4-SPM和PSA11-SPM,通过低密度脂蛋白受体非依赖性途径被摄取,并且大部分由非溶酶体鞘磷脂酶降解,该酶也催化它们在尼曼-匹克细胞中的水解。在无血清的情况下,所有鞘磷脂都通过载脂蛋白B/E受体非依赖性途径被摄取,并由非溶酶体鞘磷脂酶水解。实际上,体外试验证明淋巴母细胞中存在中性镁激活的鞘磷脂酶,其在尼曼-匹克细胞中也完全有活性。总之,我们的观察结果与以下情况一致:(i)淋巴母细胞中存在几种鞘磷脂摄取及后续利用的途径;(ii)脂蛋白在鞘磷脂代谢途径中起主要作用;(iii)鞘磷脂脂肪酰基残基的结构对其与脂蛋白和/或细胞膜可能的结合的影响。